Geoffrey von Maltzahn is Co-founder and CEO of Lila Sciences, where he is leading the company’s mission to build scientific superintelligence to solve humankind’s greatest challenges across life, chemical, and materials sciences.
Among the most successful scientific entrepreneurs of his generation, he has founded or co-founded companies whose technologies integrate biology and AI to transform human health and sustainability, achieving over $10B in public and private market capitalization. He served as founding CEO of Generate:Biomedicines (Nasdaq: GENB), Tessera Therapeutics, Quotient Therapeutics, and Indigo Ag, and is a co-founder of Sana Biotechnology (Nasdaq: SANA) and Seres Therapeutics (Nasdaq: MCRB). He is named inventor on more than 200 patents and patent applications.
Geoffrey holds a PhD in Biomedical Engineering and Medical Physics from MIT, an MS in Bioengineering from the University of California, San Diego, and an SB in Chemical Engineering from MIT.
The latest from Lila Sciences
